← All stocks

Janux Therapeutics, Inc.

JANX No buying or selling

CIK 0001817713 #2496 in the set updated 19 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$0.00

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 0 sales

Net

$0.00

$0.00 against sales at will

By person

19 insiders · 0 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Avalon Ventures XI, L.P. entity

10% owner

—

4,187,172

$58.74M

−32.0%

Campbell David Alan

President and CEO

—

264,742

$3.71M

−20.3%

DiRaimondo Thomas

Chief Scientific Officer

—

155,825

$2.19M

+44.4%

Gujrathi Sheila

Director

—

118,889

$1.67M

+7.6%

Winter Charles M.

Chief Technical Officer

—

106,321

$1.49M

+86.1%

Meyer Andrew Hollman

Chief Business Officer

—

83,095

$1.17M

+18.0%

CAPPS VICKIE L

Director

—

79,598

$1.12M

+17.0%

Doyle Janeen Noel

Chief Corp. & Bus. Dev. Ofcr

—

75,941

$1.07M

—

McIver Zachariah

Chief Medical Officer

—

52,286

$733.52K

—

Go William

Chief Medical Officer

—

44,000

$617.28K

—

Dobek Maria

Vice President, Accounting

—

32,270

$452.72K

+1,038%

Robinson Byron

Chief Strategy Officer

—

28,000

$392.81K

—

DOBMEIER ERIC

Director

—

15,481

$217.18K

+148.5%

Hernday Natasha

Director

—

15,481

$217.18K

+148.5%

RA CAPITAL MANAGEMENT, L.P. entity

Director

—

11,750

$164.84K

—

Simson Jake

Director

—

11,750

$164.84K

+370.0%

Kung Winston

Director

—

11,750

$164.84K

+370.0%

Barrett Ronald W

Director

—

11,750

$164.84K

+370.0%

McNulty Alana B.

Director

—

6,250

$87.68K

+150.0%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Janux Therapeutics, Inc.

By person

Individual transactions

What was left out